SCHEMBL1982163

SCHEMBL1982163

Nc1ccc(N2CCC3(CC2)OCCO3)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGMN Q99538 2/20 0.61
MAPT P10636 8/20 0.50
ALDH1A1 P00352 7/20 0.50
KDM4E B2RXH2 4/20 0.50
GAA P10253 4/20 0.50
POLB P06746 4/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
HTT P42858 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
MEN1 O00255 1/20 0.50
USP2 O75604 1/20 0.50
TP53 P04637 1/20 0.50
THRB P10828 1/20 0.50
ALOX15 P16050 1/20 0.50
RECQL P46063 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 1/20 0.50
GFER P55789 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749483 0.89 LGMN (0.51) LGMNMAPTALDH1A1KDM4EGAA
SCHEMBL4767032 0.82 LGMN (0.46) LGMNMAPTALDH1A1KDM4EGAA
SCHEMBL14117662 0.81 LGMN (0.54) LGMNMAPTALDH1A1KDM4EGAA
SCHEMBL15958458 0.81 MAPT (0.50) LGMNMAPTALDH1A1KDM4EGAA
SCHEMBL3795448 0.81 LGMN (0.54) LGMNMAPTALDH1A1KDM4EPOLB
SCHEMBL974758 0.81 LGMN (0.54) LGMNMAPTALDH1A1KDM4EPOLB
SCHEMBL5539112 0.81 LGMN (0.54) LGMNMAPTALDH1A1KDM4EGAA
SCHEMBL5546662 0.81 POLB (0.55) LGMNMAPTALDH1A1KDM4EGAA
SCHEMBL31380531 0.81 LGMN (0.54) LGMNMAPTALDH1A1KDM4EGAA
SCHEMBL612022 0.81 LMNA (0.55) LGMNMAPTALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12448389-B2 BRM targeting compounds and associated methods of use PRELUDE THERAPEUTICS INCORPORATED (US) 2025-10-21 US disclosed
US-20250214945-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2025-07-03 US disclosed
US-20250214987-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2025-07-03 US disclosed
EP-4506346-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF Korea University Research and Business Foundation (KR) 2025-02-12 EP disclosed
EP-4501915-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR Korea University Research and Business Foundation (KR) 2025-02-05 EP disclosed
CN-118974041-A Thiobenzimidazole derivatives or pharmaceutically acceptable salts thereof and use thereof 高丽大学校产学协力团 2024-11-15 CN disclosed
CN-118974021-A Preparation method of thiobenzimidazole derivative and novel intermediate for same 高丽大学校产学协力团 2024-11-15 CN disclosed
WO-2023191533-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR 고려대학교 산학협력단 2023-10-05 WO disclosed
WO-2023191536-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF 고려대학교 산학협력단 2023-10-05 WO disclosed
WO-2023191533-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR 고려대학교 산학협력단 2023-10-05 WO disclosed
US-20100317568-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2010-12-16 US disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
EP-2097413-A1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G Limited (GB) 2009-09-09 EP disclosed
WO-2008062182-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2008-05-29 WO disclosed
US-7022716-B2 Cyclic amine phenyl beta-3 adrenergic receptor agonists WYETH (US) 2006-04-04 US disclosed
US-20030144326-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists WYETH 2003-07-31 US disclosed
EP-1301482-A1 CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS Wyeth (US) 2003-04-16 EP disclosed
US-6525202-B2 E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination WYETH 2003-02-25 US disclosed
US-20020028835-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists WYETH 2002-03-07 US disclosed
WO-2002006232-A1 CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS WYETH (US) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144326-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 LGMN 4736/4885MAPT 565/4885ALDH1A1 1091/4885
US-20100317568-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS LGMN 270/4885MAPT 2833/4885ALDH1A1 2858/4885
US-20250214987-A1 THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR WEE1, WEE2, HADHB LGMN 2418/4885MAPT 4632/4885ALDH1A1 156/4885
US-20250214945-A1 THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF TTBK2, TUBB3, TUBB LGMN 4045/4885MAPT 157/4885ALDH1A1 3214/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 LGMN 3439/4885MAPT 2950/4885ALDH1A1 318/4885
US-20020028835-A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists ADRB1, ADRB3, ADRB2 LGMN 4736/4885MAPT 565/4885ALDH1A1 1091/4885
US-12448389-B2 BRM targeting compounds and associated methods of use ADRM1, BRDT, RBX1 LGMN 215/4885MAPT 1598/4885ALDH1A1 4038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.